Tardive Dyskinesia Therapeutics Market Analysis

Tardive Dyskinesia Therapeutics Market Analysis

Based on the drug, the global market is classified into deutetrabenazine, valbenazine and other drugs. The valbenazine segment dominated the market with revenue of USD 1.6 billion in 2023.
 

• Valbenazine, marketed under the brand name Ingrezza, is a drug specifically approved for the treatment of tardive dyskinesia (TD. The drug has demonstrated significant efficacy in reducing the symptoms of tardive dyskinesia in clinical trials, leading to improved patient outcomes. Therefore, the drug has a relatively favorable safety profile with manageable side effects, which increases its acceptance among healthcare providers and patients.
   
• Moreover, improved awareness and diagnosis among healthcare providers and advancements in diagnostic methods have led to earlier and more accurate diagnosis of TD, prompting timely intervention and treatment, thereby driving the growth of the market.
   

Based on the dosage form, the global tardive dyskinesia therapeutics market is classified into capsules, and tablets. The tablets segment dominated the market with market share of 54% in 2023.
 

• Tablets are easy to administer compared to other forms of medication, such as injections, enhancing patient compliance. Also, tablets prescribed for tardive dyskinesia have demonstrated significant efficacy in clinical trials, which boosts their adoption by healthcare providers and patients.  
   
• Further, advances in drug formulation technology have led to the development of more effective and patient-friendly tablet forms, such as extended-release tablets that require less frequent dosing. Thus, growing number of patients diagnosed with TD along with several benefits associated with tablet dosage form accelerates the market growth.
   

Based on distribution channel, the tardive dyskinesia therapeutics market is classified into hospital pharmacies, drugs store & retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to exhibit 7.4% CAGR between 2024 - 2032.
 

• Hospitals often have specialized departments and experts in neurology and psychiatry that are well-equipped to diagnose and treat TD effectively. Also, hospitals possess advanced diagnostic equipment that enables accurate and early detection of TD, facilitating timely and appropriate therapeutic interventions. Such aforementioned factors are anticipated to propel the growth of the market.
   
• Further, hospitals are frequently involved in clinical trials and research studies, providing access to cutting-edge therapies and experimental treatments that may not be available elsewhere. Thus, the adoption of latest treatments such as FDA-approved therapies and integrate them into the treatment protocols will augment the segmental growth.
  
   

In 2023, North America secured a substantial market share of 44.2% in the global tardive dyskinesia therapeutics market and is expected to dominate throughout the forecast period.
 

• The availability of well-established healthcare infrastructure and access to medical facilities, timely diagnosis and treatment for tardive dyskinesia drives the demand for tardive dyskinesia therapeutics in this region.
   
• Also, the presence key players and specialized clinics and centers with expertise in movement disorders ensures better management of the disease, thus boosting the growth of the market.
   
• Furthermore, availability of new pipeline drugs for tardive therapeutics will increase the product demand which in turn will propel the growth of the market during the forecast period.  
   

Germany to experience the highest growth rate in the market, outstripping other countries in Europe in the assessment period.
 

• The rising healthcare expenditure in Germany along with the availability of healthcare resources and reimbursement policies for neurological and psychiatric disorders ensure that patients have access to a range of treatment options, including therapeutics for tardive dyskinesia.
   
• Also, the increase in collaborations between pharmaceutical companies, academic institutions, and healthcare organizations facilitate the development and commercialization of new therapeutics for tardive dyskinesia. Such aforementioned factors are expected to supplement the country level market growth.
   

The India and China tardive dyskinesia therapeutics market is expected to grow with a significant CAGR during the forecast period.
 

• Improvements in healthcare infrastructure, including the expansion of hospitals, clinics, and healthcare facilities, can increase access to diagnosis and treatment for tardive dyskinesia. Also, the increase in the number of government initiatives and policies aimed at addressing mental health issues including National Mental Health Program (NMHP) in Inda, can cover provisions for improving access to treatment for tardive dyskinesia and related conditions.
   
• Thus, constant support from government is anticipated to foster the growth of the market in both the country.